Vera Therapeutics appoints Christopher Hite to Board of Directors

Vera Therapeutics, Inc.

Christopher Hite appointed as Class III Director effective March 5, 2026.
Initial option grant for 24,937 shares at $38.85, vesting monthly over three years.
Annual cash retainer of $45,000, pro-rated for 2026.
Eligible for annual option grants from 2027: lesser of 18,000 shares or up to $400k in grant date fair value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.